Answers are grounded in this paper and cite their sources.
New biomarkers of drug-induced liver injury (DILI) are required in the clinic and in preclinical pharmaceutical evaluation. Liver-enriched microRNAs are promising serum biomarkers of acetaminophen-induced acute liver injury in mice. The utility of circulating microRNAs as biomarkers of human acute DILI is discussed in the context of correlation with existing biomarkers of liver injury and patient outcomes in acetaminophen toxicity, mechanisms of cellular microRNA release, and their potential advantages over current clinical biomarkers of DILI.
No takes yet. Share an insight, caveat, or question.
Lewis et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: